Drug Duo May Be a Weapon Against a Common Leukemia

The phase 3 trial of more than 500 U.S. patients with chronic lymphocytic leukemia (CLL) found that a combination of rituximab and ibrutinib extended patient survival.

from WebMD Health https://ift.tt/2YFE9nO
via IFTTT